keyword
MENU ▼
Read by QxMD icon Read
search

adverse drug withdrawal reactions

keyword
https://www.readbyqxmd.com/read/29457009/acneiform-rash-caused-by-an-unlikely-drug-topiramate
#1
Yesenia Bello-Hernández, Jessica Espinoza-Hernández, Gabriela Moreno-Coutiño
Topiramate is an antiepileptic drug that can also be used for migraine prophylaxis, weight control, and even for methamphetamine dependence; the dosage margin is wide, and the list of side effects is shorter than with other anticonvulsants. We present the case of a 35-year-old man with a disseminated rash of the trunk and extremities after treatment with 25 mg of topiramate daily as a prophylactic migraine treatment. This case report is useful, as this patient was not polymedicated and had a score of 7 on the Naranjo Adverse Drug Reaction Probability Scale...
January 2018: Skin Appendage Disorders
https://www.readbyqxmd.com/read/29362275/investigation-assessing-the-publicly-available-evidence-supporting-postmarketing-withdrawals-revocations-and-suspensions-of-marketing-authorisations-in-the-eu-since-2012
#2
Samantha Lane, Elizabeth Lynn, Saad Shakir
OBJECTIVES: To assess the sources of publicly available evidence supporting withdrawal, revocation or suspension of marketing authorisations ('regulatory actions') due to safety reasons in the EU since 2012 and to investigate the time taken since initial marketing authorisation to reach these regulatory decisions. SETTING: This investigation examined the sources of evidence supporting 18 identified prescription medicinal products which underwent regulatory action due to safety reasons within the EU in the period 1 July 2012 to 31 December 2016...
January 23, 2018: BMJ Open
https://www.readbyqxmd.com/read/29350109/tertiary-care-experience-of-sorafenib-in-the-treatment-of-progressive-radioiodine-refractory-differentiated-thyroid-carcinoma-a-korean-multicenter-study
#3
Mijin Kim, Tae Hyuk Kim, Dong Yeob Shin, Dong-Jun Lim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, YoungKee Shong, Bo Hyun Kim, Won Gu Kim
BACKGROUND: Sorafenib, a multi-kinase inhibitor, is approved for the treatment of patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). In this study, we evaluated the efficacy and safety of sorafenib in real-world clinical practice and compared the results with those of the DECISION trial. We also evaluated the clinical features associated with better clinical outcomes after sorafenib treatment. METHODS: This multicenter, retrospective cohort study evaluated 98 patients with progressive RAI-refractory DTC who were treated with sorafenib in six tertiary hospitals in Korea...
January 19, 2018: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/29343941/clinical-features-of-hypophosphatemic-osteomalacia-induced-by-long-term-low-dose-adefovir-dipivoxil
#4
Sheng Zhu, Yu-Hui Yang, Rong-Wei Gao, Ran Li, Yu-Zhen Zou, Lei Feng, Bo Zhang
Objective: To investigate the predictors of hypophosphatemic osteomalacia induced by adefovir dipivoxil (ADV) and to monitor for early detection. Patients and methods: Hospitalized patients who were diagnosed with ADV-related hypo-phosphatemic osteomalacia were recruited and retrospectively analyzed in our hospital from January 2012 to December 2016. A telephone interview was conducted at 1, 3, 6, 9, 12, and 24 months after cessation of ADV. Results: In the 8 patients enrolled in the study, the hypophosphatemic osteomalacia symptoms developed at an average of 5...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29343268/time-homogeneous-markov-process-for-hiv-aids-progression-under-a-combination-treatment-therapy-cohort-study-south-africa
#5
Claris Shoko, Delson Chikobvu
BACKGROUND: As HIV enters the human body, its main target is the CD4 cell which it turns into a factory that produces millions of other HIV particles. These HIV particles target new CD4 cells resulting in the progression of HIV infection to AIDS. A continuous depletion of CD4 cells results in opportunistic infections, for example tuberculosis (TB). The purpose of this study is to model and describe the progression of HIV/AIDS disease in an individual on antiretroviral therapy (ART) follow up using a continuous time homogeneous Markov process...
January 18, 2018: Theoretical Biology & Medical Modelling
https://www.readbyqxmd.com/read/29282040/case-report-atypical-presentation-of-vancomycin-induced-dress-syndrome-a-case-report-and-review-of-the-literature
#6
Olivia Wilcox, Mohamed Hassanein, John Armstrong, Nader Kassis
BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe hypersensitivity drug reaction involving the skin and multiple internal organ systems. The symptoms typically present with fever and skin rash, and rapidly progress to multiple organ failures. Vancomycin is a rare drug to cause DRESS syndrome with 23 cases reported to date. CASE PRESENTATION: We described a case of a 39 year-old man who was treated with vancomycin for osteomyelitis of the foot...
December 28, 2017: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29274824/antituberculosis-drug-associated-dress-a-case-series
#7
Marion Allouchery, Sophie Logerot, Judith Cottin, Pauline Pralong, Céline Villier, Benoit Ben Saïd
BACKGROUND: Although antituberculosis drug-associated drug reaction with eosinophilia and systemic symptoms (DRESS) is rarely reported, its diagnosis should not be dismissed. Its management implies an early withdrawal of suspected drugs. OBJECTIVE: The objective of this study was to describe the characteristics of antituberculosis drug-associated DRESS and to identify the most likely involved drugs. METHODS: We searched for potential cases of DRESS with rifampicin, isoniazid, pyrazinamide, and ethambutol reported from January 1, 2005, to July 30, 2015, in the French pharmacovigilance database...
December 20, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29239026/early-cutaneous-eruptions-after-oral-hydroxychloroquine-in-a-lupus-erythematosus-patient-a-case-report-and-review-of-the-published-work
#8
Tomoko Matsuda, Nhung Thi My Ly, Naotomo Kambe, Chuyen Thi Hong Nguyen, Ikuko Ueda-Hayakawa, Yonsu Son, Hiroyuki Okamoto
Hydroxychloroquine (HCQ) is an effective treatment of lupus erythematosus. Although adverse effects, mainly gastrointestinal and cutaneous manifestations, are rare, they may result in the cessation of medication in some patients with severe reactions. Therefore, the evaluation of a patient's condition is important for a dermatologist to decide whether to cease or continue HCQ. We herein report a case of a 36-year-old Japanese woman with systemic lupus erythematosus and cutaneous eruptions caused by the p.o...
December 14, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/29224298/-smoking-abstinence-rate-and-its-associated-factors-between-abrupt-and-gradual-smoking-cessation
#9
R Hao, J P Zhou, L Ni, Q Y Li, G C Shi
Objective: To analyze and compare the abstinence rate of smoking quitting methods and its associated factors between abrupt and gradual smoking cessation in smokers with drug-based therapy. Methods: A prospective clinical study was conducted in patients undergoing quitting smoking intervention in Ruijin Hospital smoking cessation clinic between June 2013 and May 2016. All the subjects were randomized in a 1∶1 ratio into the abrupt smoking cessation group (smoking as usual over 3 weeks before a planned quit day, and then stopping smoking abruptly) and the gradual smoking cessation group (gradually reducing tobacco use over 3 weeks before a planned quit day, and then stopping smoking totally)...
December 12, 2017: Chinese Journal of Tuberculosis and Respiratory Diseases
https://www.readbyqxmd.com/read/29217288/avelumab-in-metastatic-urothelial-carcinoma-after-platinum-failure-javelin-solid-tumor-pooled-results-from-two-expansion-cohorts-of-an-open-label-phase-1-trial
#10
Manish R Patel, John Ellerton, Jeffrey R Infante, Manish Agrawal, Michael Gordon, Raid Aljumaily, Carolyn D Britten, Luc Dirix, Keun-Wook Lee, Mathew Taylor, Patrick Schöffski, Ding Wang, Alain Ravaud, Arnold B Gelb, Junyuan Xiong, Galit Rosen, James L Gulley, Andrea B Apolo
BACKGROUND: The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed death 1 agents has expanded treatment options for patients with locally advanced or metastatic urothelial carcinoma. Avelumab, a human monoclonal anti-PD-L1 antibody, has shown promising antitumour activity and safety in this disease. We aimed to assess the safety profile in patients (both post-platinum therapy and cisplatin-naive) treated with avelumab and to assess antitumour activity of this drug in post-platinum patients...
December 4, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29210868/is-there-a-potential-of-misuse-for-quetiapine-literature-review-and-analysis-of-the-european-medicines-agency-european-medicines-agency-adverse-drug-reactions-database
#11
Stefania Chiappini, Fabrizio Schifano
PURPOSE/BACKGROUND: A recent years' increase in both prescribing and availability of second-generation antipsychotics (SGAs) has been observed. According to the literature, typically made up by case studies/series, quetiapine seems to be the most commonly misused SGA, with both intranasal and intravenous intake modalities having been described. Another SGA that has been anecdotally reported to be misused is olanzapine. For these molecules, both a previous history of drug misuse and being an inmate have been described as factors associated with misuse...
February 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29205444/switching-from-infliximab-innovator-to-biosimilar-in-patients-with-inflammatory-bowel-disease-a-12-month-multicentre-observational-prospective-cohort-study
#12
E M H Schmitz, P J Boekema, J W A Straathof, D C van Renswouw, L Brunsveld, V Scharnhorst, M E C van de Poll, M A C Broeren, L J J Derijks
BACKGROUND: Infliximab biosimilars have become available for treatment of inflammatory bowel disease (IBD). However, data showing long-term safety and effectiveness of biosimilars in IBD patients are limited. AIM: To study prospectively the switch from infliximab innovator to biosimilar in an IBD cohort with 12 months follow-up to evaluate safety and effectiveness. METHODS: Adult IBD patients from two hospitals treated with infliximab innovator (Remicade; Janssen Biotech,  Horsham ,  Pennsylvania, USA) were switched to infliximab biosimilar (Inflectra; Hospira, Lake Forest, Illinois, USA) as part of routine care, but in a controlled setting...
December 5, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29199808/how-to-identify-dress-drug-reaction-with-eosinophilia-and-systemic-symptoms
#13
Piia Sarajärvi, Minna Kubin, Kaisa Tasanen, Laura Huilaja
DRESS (drug reaction with eosinophilia and systemic symptoms) is a rare, severe multiorgan adverse drug reaction. Antiepileptic age's and antibiotics are the most frequently reported causative agents. Compared with other drug reactions, DRESS demonstrates a long latency period thus complicating recognition and diagnosis. DRESS is defined as presence of fever, skin eruption, hematologic abnormalities and systemic involvement, especially liver injury. Withdrawal of the culprit drug, commencement of systemic corticosteroid and supportive care are the mainstay of treatment...
2017: Duodecim; Lääketieteellinen Aikakauskirja
https://www.readbyqxmd.com/read/29190196/clinical-and-histologic-features-of-acute-onset-erythroderma-in-dogs-with-gastrointestinal-disease-18-cases-2005-2015
#14
Christine L Cain, Charles W Bradley, Elizabeth A Mauldin
OBJECTIVE To describe the clinical and histologic features of acute erythroderma in dogs with gastrointestinal disease. DESIGN Retrospective case series. ANIMALS 18 dogs with erythroderma and gastrointestinal disease. PROCEDURES Medical records and biopsy specimens were reviewed. Information collected from medical records included signalment, clinical signs, physical examination and diagnostic test results, treatment, and outcome. The Naranjo algorithm was used to estimate the probability of an adverse drug reaction for each dog...
December 15, 2017: Journal of the American Veterinary Medical Association
https://www.readbyqxmd.com/read/29168605/what-psychologists-need-to-know-about-psychotropic-medications
#15
Elena Tomba, Jenny Guidi, Giovanni A Fava
Despite the fact that today most of the patients with psychological disturbances assume some form of psychotropic drug treatment, clinical psychologists may have little familiarity with psychopharmacology and are substantially unaware of subtle and yet pervasive potential effects of medications in clinical presentations. In their training, psychologists are generally exposed, at best, to some general principles of drug action. Standard psychopharmacology textbooks tend to omit the subtle psychological changes that may occur during psychotropic drug treatment...
November 23, 2017: Clinical Psychology & Psychotherapy
https://www.readbyqxmd.com/read/29145260/reversible-severe-fatty-liver-induced-by-capecitabine-a-case-report
#16
Yiyan Jiang, Qiancheng He, Suxia Li, Chang Shi, Xiaolei Yang
RATIONALE: Capecitabine (CAP) is a chemotherapeutic agent used to treat breast and gastrointestinal cancers. The most common adverse reactions of CAP primarily included gastrointestinal and dermatological effects. Whereas, the CAP-induced fatty liver had never been reported. PATIENT CONCERNS: In this study, a-69-year old female presented a history of hypertension with regulated blood pressure, whereas diabetes mellitus, hyperlipidemia, and hepatitis were excluded...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29081616/biological-response-modifiers-in-rheumatoid-arthritis-systematic-review-and-meta-analysis-of-safety
#17
Nitishkumar D Tank, Bharti N Karelia, Bhavisha N Vegada
OBJECTIVE: To analyze available evidence on the safety of different biological response modifiers which are used for a treatment of rheumatoid arthritis (RA). MATERIALS AND METHODS: We searched systematically for randomized controlled clinical trials on treatment of RA with different biological response modifiers, followed by a systematic review with meta-analysis. Trials were searched from MEDLINE and Cochrane Library databases. The following safety parameters reported in the selected trials were analyzed: number of patients suffering any adverse event (AE), withdrawal due to AEs, serious AE (SAEs), infections, serious infections, infusion reactions, injection site reactions, malignancies, and overall mortality...
July 2017: Journal of Pharmacology & Pharmacotherapeutics
https://www.readbyqxmd.com/read/29076385/post-marketing-withdrawal-of-analgesic-medications-because-of-adverse-drug-reactions-a-systematic-review
#18
Igho J Onakpoya, Carl J Heneghan, Jeffrey K Aronson
Many analgesics have been withdrawn from the market because of adverse drug reactions. Controversy still surrounds the use of some approved analgesics for pain management. However, the trends and reasons for withdrawal of analgesics when harms are attributed to their use have not been systematically assessed. Areas covered: We conducted searches in PubMed; Embase; Google Scholar; clinicaltrials.gov; WHO databases of withdrawn products; websites of the European Medicines Agency, the US Food and Drug Administration, the UK Medicines and Healthcare products Regulatory Agency; Meyler's Side Effects of Drugs; Stephens' Detection of New Adverse Drug Reactions; the Pharmaceutical Manufacturing Encyclopedia; and the Merck Index...
November 1, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29074415/non-steroidal-anti-inflammatory-drugs-are-safe-with-respect-to-the-transcriptome-of-human-dermal-fibroblasts
#19
Paweł Mozolewski, Joanna Jakóbkiewicz-Banecka, Grzegorz Węgrzyn, Bogdan Banecki, Magdalena Gabig-Cimińska
Non-steroidal anti-inflammatory drugs (NSAIDs) provide important benefits to millions of patients, but are associated with a number of serious adverse events. These adverse drug reactions are an important clinical issue and a serious public health risk. While most unfortunate responses in human to NSAIDs are mild and may disappear after decreasing the dose or withdrawal of the drug, some of them can produce serious outcomes. Currently, little is known regarding the effects of NSAIDs on global RNA expression in normal, non-transformed cells...
October 24, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29074353/clinical-features-of-regorafenib-induced-liver-injury-in-japanese-patients-from-postmarketing-experience
#20
Hiroyuki Uetake, Kenichi Sugihara, Kei Muro, Toshiyuki Sunaya, Yuka Horiuchi-Yamamoto, Hajime Takikawa
BACKGROUND: Regorafenib (Stivarga) is an oral multikinase inhibitor currently approved for patients with metastatic colorectal cancer or gastrointestinal stromal tumor. Although hepatotoxicity has been a known product profile feature of regorafenib since its initial approval, its clinical features are limited to those found in the clinical trials. PATIENTS AND METHODS: The present study was conducted in 2 analysis sets: a safety analysis set for metastatic colorectal cancer from solicited postmarketing surveillance (PMS) in Japan (n = 1227) and an analysis set for serious hepatic adverse drug reactions (n = 210) from all patients registered for regorafenib use...
September 28, 2017: Clinical Colorectal Cancer
keyword
keyword
27076
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"